Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551053 · ClinicalTrials.gov registry record · Phase 3
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
A Phase 3 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
NCT04551053 is a Phase 3 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 177 participants.
The verdict
NCT04551053, a Phase 3 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.
Interventions
- DRUG placebo
- DRUG ruxolitinib
- DRUG parsaclisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2021-05-26 |
| Est. Completion | 2024-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04551053
The ClinicalTrials.gov registry entry for NCT04551053 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT04551053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04551053 about?
NCT04551053 is a clinical study titled "To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)". The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.
What is the current status of trial NCT04551053?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2021-05-26. Estimated completion is 2024-08-21.
What interventions are being tested in trial NCT04551053?
The interventions under investigation include: placebo (DRUG), ruxolitinib (DRUG), parsaclisib (DRUG).
Who is sponsoring clinical trial NCT04551053?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.